June 12, 2017. By Gordon Gibb.
New Orleans, LA: There is speculation that a bellwether Xarelto lawsuit, currently underway in the state of Louisiana, may end as the first bellwether concluded; with a verdict for the defense. However, legal commentator Tighe Wilhelmy of Velawcity notes that Louisiana’s ‘Learned Intermediary Doctrine Defense’ may not necessarily apply going forward to cases whose original jurisdictions fall outside the state of Louisiana.Read [ Forecasting the Xarelto Bellwether Trials ]
May 28, 2017. By Brenda Craig.
New Orleans, LA On May 30, 2017, a courtroom in New Orleans will hear testimony for another major bell weather case involving the controversial blood thinner drug Xarelto and the late Sharyn Orr from Kenner, Louisiana.Read [ Claims against Xarelto Due to Be Tested in Court Again ]
May 12, 2017. By Gordon Gibb.
New Orleans, LA: The long-anticipated first bellwether trial in multidistrict litigation for Xarelto side effects has gone to the defendants. Plaintiff Joseph Boudreaux’s trial commenced April 24 and all eyes were on the litigation as an indicator as to how other bellwether trials might go.Read [ First Xarelto Bellwether Trial Goes to the Defense ]
April 11, 2017. By Gordon Gibb.
Philadelphia, PA: As the Philadelphia Xarelto mass tort moves closer towards the bellwether trial stage, Xarelto principles Bayer AG and Janssen Pharmaceuticals have signaled that they want to know the identity of any third-party funders associated with Xarleto bleeding issue lawsuits. In other words, the defendants want to know how plaintiffs are funded.Read [ Defendants on Philadelphia Xarelto Mass Tort Seek Disclosure of Third-Party Funding ]
March 1, 2017. By Gordon Gibb.
New Orleans, LA: It could be mere co-incidence, but on the eve of the National Basketball Association (NBA) All Star Game that served to delay Xarelto bellwether trials by a month, the manufacturers of Xarelto chose to highlight an aging NBA all-star player who expounds upon the virtues of rivaroxaban (Xarelto) and professes to use it himself. As such, a visit to the official Xarelto website showcases the former All-American player, rather than the potential for a Xarelto bleeding issue.Read [ Plaintiffs Looking for a Slam Dunk in First Xarelto Bellwether Trial This Month ]
February 3, 2017. By Gordon Gibb.
New Orleans, LA: The maiden bellwether Xarelto lawsuit was originally scheduled to commence this month, an important event given that the number of Xarelto Bleeding Issue cases now exceeds 10,000.Read [ Xarelto Bellwether Pushed Back by NBA All-Star Game ]
January 6, 2017. By Gordon Gibb.
Orleans, LA: The massive Xarelto lawsuit portfolio, currently with almost 14,000 cases pending in multidistrict litigation, will see its first bellwether trial roll out in March with additional bellwethers slated for April and May. Plaintiffs allege that Xarelto, a blood thinner, triggered Xarelto bleeding complications without benefit of an available antidote to reverse the blood thinning properties of the anticoagulant.Read [ First Xarelto Bellwether Trial Due in March, Others to Follow in 2017 ]
December 5, 2016. By Gordon Gibb.
Washington, DC: In spite of assurances by the US Food and Drug Administration (FDA) that a recall of a monitoring device used to help determine the safety and effectiveness of Xarelto did not adversely affect outcomes, some 7,200 Xarelto lawsuits have been filed and consolidated in multidistrict litigation. The first bellwether Xarelto lawsuit is now only months away, scheduled for February of next year.Read [ FDA Assurances Likely Not Enough to Satisfy Xarelto Litigants ]
November 2, 2016. By Jane Mundy.
Philadelphia, PA: To date, 950 Xarelto lawsuits that have been consolidated into a mass tort will be tried under the bellwether program slated for next summer at the earliest. Additionally, almost 3,000 cases make up the federal Xarelto multi-district litigation (MDL).Read [ Xarelto Mass Tort and MDL Grows ]
October 2, 2016. By Gordon Gibb.
New Orleans, LA: The expected wave of litigation stemming from Xarelto Bleeding complications has come to pass, with a parade of cases continuing to find harbor in Multi-District Litigation (In Re Xarelto MDL 2592, US District Court, Eastern District of Louisiana). More than 7,000 cases are pending, with the expectation of further cases given the deadline extension issued last month by US District Court Judge Eldon Fallon.Read [ Xarelto MDL Judge Orders Redacted Personnel Files of Two Bayer Doctors ]